Anti-B7-H1/PD-L1/CD274 Antibody (Atezolizumab)
Catalog No.
F1310
Anti-B7-H1/PD-L1/CD274 Antibody (Atezolizumab)
Featured Products
Atezolizumab (CAS 1380723-44-3) is a humanized monoclonal antibody of the IgG1 class targeting programmed death-ligand 1 (PD-L1), also known as B7-H1 or CD274. It functions by selectively binding to PD-L1, thereby preventing interactions between PD-L1 and its receptor PD-1. This blockade helps restore suppressed immune responses, particularly T-cell-mediated tumor surveillance. In biomedical research, atezolizumab serves as a tool in studies investigating immune checkpoint signaling pathways and immunotherapeutic strategies against various cancers.
Quality Control & DataSheet
- View current batch:
-
Purity > 95% by SDS-PAGE and SEC-HPLC analyses.
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
- Datasheet
145 kDa
Dry ice
1380723-44-3
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
RG-7446, RO-5541267
100 mM Pro 20 mM Arg pH 5.0. No preservative!
Q9NZQ7
Human, Mouse, Cynomolgus
Unconjugated
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
Immobilized human PD-L1 His at 2 ug/mL can bind Anti-B7-H1/PD-L1/CD274 Antibody (Atezolizumab)
B7-H1 / PD-L1 / CD274
Please avoid freeze-thaw cycles.